MRK · News · 20261102N

HIV Pipeline Progress

Merck & Co., Inc. · 2026-11-02 · Importance 28 · Surprise 24

Merck plans to present data at HIV Drug Therapy Glasgow 2026 on daily and investigational once-weekly oral HIV treatments and investigational once-monthly oral pre-exposure prophylaxis. The data include Phase 3 subgroup analyses and patient-reported outcomes for the investigational once-weekly islatravir/lenacapavir combination. These dosing approaches expand Merck’s oral treatment and prevention pipeline beyond daily regimens.

Key facts

• Merck announced that new data across its HIV treatment and prevention pipeline and portfolio will be presented at HIV Drug Therapy Glasgow 2026, taking place Nov. 8–11, 2026, in Glasgow, Scotland. source
• Merck will present Phase 3 subgroup analyses and patient-reported outcomes for its investigational once-weekly oral combination of islatravir/lenacapavir (ISL/LEN). source
• Merck plans to present fresh clinical data from its HIV portfolio at the HIV Glasgow 2026 congress. source